These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 36528754)

  • 21. Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome.
    Santiago V; Lazaryan A; McClune B; McKenna RW; Courville EL
    Leuk Lymphoma; 2018 Apr; 59(4):958-966. PubMed ID: 28728454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granular lymphoproliferative disorder, autologous blood stem cell transplantation and multiple myeloma.
    Rey J; Olive D; Gastaut JA; Costello RT
    Eur J Haematol; 2003 Oct; 71(4):311-2. PubMed ID: 12950244
    [No Abstract]   [Full Text] [Related]  

  • 23. The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT).
    Świerzko AS; Michalski M; Sokołowska A; Nowicki M; Eppa Ł; Szala-Poździej A; Mitrus I; Szmigielska-Kapłon A; Sobczyk-Kruszelnicka M; Michalak K; Gołos A; Wierzbowska A; Giebel S; Jamroziak K; Kowalski ML; Brzezińska O; Thiel S; Jensenius JC; Kasperkiewicz K; Cedzyński M
    Front Immunol; 2018; 9():2153. PubMed ID: 30294330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of infectious events by the high-sensitivity C-reactive protein level before autologous hematopoietic cell transplantation for lymphoma and multiple myeloma.
    Sato M; Nakasone H; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Kawamura K; Ashizawa M; Machishima T; Terasako K; Kimura SI; Kikuchi M; Tanihara A; Yamazaki R; Tanaka Y; Kanda J; Kako S; Nishida J; Kanda Y
    Transpl Infect Dis; 2013 Aug; 15(4):E169-71. PubMed ID: 23782409
    [No Abstract]   [Full Text] [Related]  

  • 26. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
    Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
    Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloma stem cells in autografting in multiple myeloma.
    To LB; Horvath N; Dyson P; Henry J; Sykes P; Brisco M; Morley A; Bennetts B
    J Hematother; 1996 Oct; 5(5):557-9. PubMed ID: 8938529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma.
    Nagayama T; Ashizawa M; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Ann Hematol; 2020 Dec; 99(12):2893-2901. PubMed ID: 32572522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma.
    Gupta R; Kumar L; Dahiya M; Mathur N; Harish P; Sharma A; Sharma OD; Shekhar V
    Leuk Lymphoma; 2017 May; 58(5):1234-1237. PubMed ID: 27658735
    [No Abstract]   [Full Text] [Related]  

  • 30. Toward a more rational policy for autologous hematopoietic stem cell mobilization.
    Devine SM
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1468-70. PubMed ID: 22892553
    [No Abstract]   [Full Text] [Related]  

  • 31. Survivorship after Autologous Hematopoietic Cell Transplantation for Lymphoma and Multiple Myeloma: Late Effects and Quality of Life.
    Georges GE; Bar M; Onstad L; Yi JC; Shadman M; Flowers ME; Carpenter PA; Stewart S; Lee SJ; Holmberg LA
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):407-412. PubMed ID: 31605822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey.
    Pierelli L; Berto P; Accorsi P; Milone G; Lopatriello S; Aiello A; Iacopino P; Olivieri A; Rambaldi A; Bosi A
    Transfus Apher Sci; 2013 Dec; 49(3):615-22. PubMed ID: 23973731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Chong CY
    Clin J Oncol Nurs; 2022 Jun; 26(3):252-256. PubMed ID: 35604735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery.
    Ungerstedt JS; Watz E; Uttervall K; Johansson BM; Wahlin BE; Näsman P; Ljungman P; Gruber A; Axdorph Nygell U; Nahi H
    Med Oncol; 2012 Sep; 29(3):2191-9. PubMed ID: 21779930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels.
    Eicher F; Mansouri Taleghani B; Schild C; Bacher U; Pabst T
    Hematol Oncol; 2020 Oct; 38(4):523-530. PubMed ID: 32594534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of oxidative stress and DNA damage with grafting time in patients with multiple myeloma and lymphoma submitted to autologous hematopoietic stem cell transplantation.
    Santos TN; Duarte FB; Maia Filho PA; Santos TE; Barbosa MC; Almeida Filho TP; Cavalcanti BC; Vasconcelos PR; Dutra LL; Lopes GS; Costa FO; Leitão JP; KauFman J; AraúJo BS; Barroso KS; Lemes RP
    Rev Assoc Med Bras (1992); 2016 Oct; 62 Suppl 1():39-43. PubMed ID: 27982318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation.
    Chitre S; Stölzel F; Cuthill K; Streetly M; Graham C; Dill C; Mohamedali A; Smith A; Schetelig J; Altmann H; Bornhäuser M; Mufti GJ
    Leukemia; 2018 Sep; 32(9):2020-2024. PubMed ID: 30026569
    [No Abstract]   [Full Text] [Related]  

  • 38. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma.
    Auner HW; Sill H; Mulabecirovic A; Linkesch W; Krause R
    Ann Hematol; 2002 Jul; 81(7):374-7. PubMed ID: 12185506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma.
    Moor I; Bacher VU; Jeker B; Taleghani BM; Mueller BU; Keller P; Betticher D; Egger T; Novak U; Pabst T
    Bone Marrow Transplant; 2018 Dec; 53(12):1599-1602. PubMed ID: 29884856
    [No Abstract]   [Full Text] [Related]  

  • 40. Autologous hematopoietic cell transplantation: an update for clinicians.
    Hamadani M
    Ann Med; 2014 Dec; 46(8):619-32. PubMed ID: 25211470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.